Clinic
Advanced Hematology Oncology, PLLC
Advanced Hematology Oncology, PLLC was paid $4.42M by Medicaid between Jan 2018 and Dec 2024, across 60 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 35% of everything it billed.
33Billing provider infoADVANCED HEMATOLOGY ONCOLOGY, PLLC
FLUSHING, NY 11355
FLUSHING, NY 11355
33aNPI1659541696assigned 03/05/2008
33bProvider typeHealth Service Clinic/Center
28Total paid$4.42M
24GClaims128,615
24DCodes billed60
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Health Service Clinic/Center providers in New York
Rank by total paid#11 of 54
Median peer was paid$410K
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,812 | $555K | |
| 2019 | 21,670 | $735K | |
| 2020 | 21,980 | $686K | |
| 2021 | 24,373 | $797K | |
| 2022 | 18,665 | $620K | |
| 2023 | 17,712 | $621K | |
| 2024incomplete | 11,403 | $406K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 35% | 17,790 | 12,089 | $1.54M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 14% | 5,121 | 5,007 | $638K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 11% | 3,746 | 1,962 | $501K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 6.2% | 3,675 | 1,638 | $274K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 4.8% | 3,842 | 1,536 | $211K |
| 96367 | 4.3% | 2,684 | 1,395 | $189K | |
| 99205 | Prolong outpt/office vis | 4.2% | 832 | 830 | $185K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.9% | 722 | 721 | $127K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.6% | 18,251 | 14,886 | $115K |
| 96522 | 1.8% | 795 | 415 | $81K | |
| 96417 | 1.4% | 571 | 332 | $60K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 3,765 | 1,662 | $59K |
48 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 3,697 | $56K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 1,275 | $51K |
| A4221 | Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately) | 1.1% | 5,855 | $51K |
| 36593 | 1.0% | 1,352 | $46K | |
| Q0081 | Infusion therapy, using other than chemotherapeutic drugs, per visit | <1% | 1,884 | $37K |
| 96415 | <1% | 825 | $36K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 703 | $29K |
| A4222 | Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately) | <1% | 2,197 | $23K |
| Q0084 | Chemotherapy administration by infusion technique only, per visit | <1% | 1,247 | $19K |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,705 | $13K |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 867 | $10K |
| 99442 | <1% | 179 | $10K | |
| 96401 | <1% | 173 | $10K | |
| 99406 | <1% | 497 | $7K | |
| H0001 | Alcohol and/or drug assessment | <1% | 658 | $6K |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 615 | $5K |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 430 | $5K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 94 | $2K |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 2,199 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,044 | $2K |
| 99497 | <1% | 32 | $2K | |
| 99245 | <1% | 14 | $2K | |
| 99195 | <1% | 18 | $2K | |
| 96523 | <1% | 2,122 | $1K | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 4,268 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 422 | $1K |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 2,947 | $889.00 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 22 | $868.13 |
| 3078F | <1% | 243 | $460.00 | |
| 3074F | <1% | 246 | $449.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,444 | $367.02 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,339 | $235.05 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 103 | $227.10 |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,394 | $208.56 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,189 | $137.65 |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 14 | $75.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 34 | $38.99 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 291 | $4.28 |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | <1% | 742 | $1.29 |
| 1126F | 0% | 331 | $0.00 | |
| 1000F | 0% | 192 | $0.00 | |
| 1036F | 0% | 391 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 444 | $0.00 |
| G8418 | Bmi is documented below normal parameters and a follow-up plan is documented | 0% | 95 | $0.00 |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | 0% | 88 | $0.00 |
| 3725F | 0% | 231 | $0.00 | |
| 3288F | 0% | 367 | $0.00 | |
| 1494F | 0% | 302 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHE, ZILI (OWNER)